Celosia Therapeutics Pty Ltd

This early-stage study is testing the safety of a new gene therapy called CTx1000 in people with ALS. The therapy aims to target a protein called TDP-43 that builds up in ALS. Researchers will give a single dose to 15 participants and closely monitor for side effects while also c…